Sector
PharmaceuticalsOpen
₹220Prev. Close
₹217.6Turnover(Lac.)
₹33.99Day's High
₹221Day's Low
₹212.152 Week's High
₹396.9552 Week's Low
₹190Book Value
₹31.98Face Value
₹10Mkt Cap (₹ Cr.)
255.52P/E
31.53EPS
6.82Divi. Yield
0.236 Aug 2024
12:00 AM
AGM
Announcement Date: 06 Aug, 2024
21 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 13.71 | 10 | 10 | 8.5 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 14.19 | -13.07 | -17.58 | -53.39 |
Net Worth | 27.9 | -3.07 | -7.58 | -44.89 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 25.09 | 16.35 | 17.95 | 32.66 |
yoy growth (%) | 53.46 | -8.92 | -45.02 | -71.71 |
Raw materials | -14.8 | -9.06 | -25.38 | -28.15 |
As % of sales | 58.98 | 55.43 | 141.36 | 86.19 |
Employee costs | -2.49 | -2.61 | -2.96 | -2.77 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 1.41 | -1.8 | -53.37 | -26.41 |
Depreciation | -0.85 | -1.07 | -1.19 | -1.19 |
Tax paid | 0 | 0.1 | 0.31 | 0.19 |
Working capital | 2.96 | 8.78 | -54.83 | -23.02 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 53.46 | -8.92 | -45.02 | -71.71 |
Op profit growth | -744.32 | -99.36 | 124.45 | 321.48 |
EBIT growth | -233.46 | -97.82 | 144.81 | 251.42 |
Net profit growth | -183.08 | -96.78 | 102.35 | 79.09 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 |
|---|---|---|
Gross Sales | 70.1 | 54.41 |
Excise Duty | 0 | 0 |
Net Sales | 70.1 | 54.41 |
Other Operating Income | 0 | 0 |
Other Income | 1.22 | 0.52 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.3 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,613.75 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,512.75 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.2 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,225.7 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Ashwin Khemka
Independent Director
Mrunmai M Sarvankar
Independent Director
Monika Singhania
Executive Director
Srivardhan Ashwani Khemka
Independent Director
Abhay Shah
205 P N Khotari Indl Estate,
LBS Marg Bhandup (West),
Maharashtra - 400078
Tel: 91-22-67290900
Website: http://www.sanjivani.co.in
Email: [email protected]; [email protected], s
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: [email protected]
Summary
Sanjivani Paranteral Ltd is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decad...
Read More
Reports by Sanjivani Paranteral Ltd
What is the Sanjivani Paranteral Ltd share price today?
What is the Market Cap of Sanjivani Paranteral Ltd?
What is the PE and PB ratio of Sanjivani Paranteral Ltd?
What is the 52 Week High and Low of Sanjivani Paranteral Ltd?
What is the CAGR of Sanjivani Paranteral Ltd?
What is the shareholding pattern of Sanjivani Paranteral Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.